Elite Pharmaceuticals Stock Price Drops Below 200-Day Average

Analysts see better opportunities elsewhere as company's shares decline

Mar. 20, 2026 at 7:51am

Got story updates? Submit your updates here. ›

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP), a specialty pharmaceutical company focused on complex drug formulations, has seen its stock price fall below its 200-day moving average. The company's shares traded as low as $0.3705 on Thursday, closing at $0.3765 with a trading volume of 188,371 shares.

Why it matters

A stock's price falling below its 200-day moving average is often seen as a bearish signal, indicating a potential downward trend. This development raises questions about Elite Pharmaceuticals' performance and the outlook for the company's business.

The details

Elite Pharmaceuticals has a current ratio of 7.34, a quick ratio of 5.44, and a debt-to-equity ratio of 0.05. The company's 50-day moving average is $0.42, while the 200-day moving average is $0.53. Elite Pharmaceuticals has a market capitalization of $405.53 million, a price-to-earnings ratio of 12.55, and a beta of 0.35.

  • Elite Pharmaceuticals' stock price crossed below its 200-day moving average on Thursday, March 20, 2026.
  • The company's most recent earnings report was announced on Tuesday, February 17, 2026.

The players

Elite Pharmaceuticals, Inc.

A U.S.-based specialty pharmaceutical company that acquires, develops, and markets both branded and generic pharmaceutical products, with a focus on complex dosage forms and addressing unmet medical needs.

Got photos? Submit your photos here. ›

What’s next

Analysts will likely be closely watching to see if Elite Pharmaceuticals' stock price can recover and regain its 200-day moving average, or if the downward trend continues.

The takeaway

The decline in Elite Pharmaceuticals' stock price below its 200-day moving average raises concerns about the company's performance and outlook, with analysts suggesting there may be better investment opportunities elsewhere in the market.